NEWS : CIMS Healthcare Excellence Awards 2017- Best Hospital Unit in Oncology & Individual Excellence in the field of Operations * Padmashree Dr. Ramakant Deshpande, Executive Chairman and Director of ACI, receiving an award for the Best Healthcare Entrepreneur at Global Awards for Excellence in Quality Management & Leadership * ACI DAYCARE-BORIVALI 4 Feb launching of centre by the hands of cabinet Minister Shree Vinod Tawde & sitting MP Shree Gopal Shetty * Click Here To Take Appointment!!! * We have Sucessfully performed 250 Robotic Surgery till date *
BLOG : Afatinib Superior to Erlotinin Liquid Biopsy gives 100% accuracy Head and Neck New Urinary Molecular Test

Patients with chronic phase chronic myeloid leukemia (CML) and pre-existing mild to moderate liver and/or renal dysfunction can be safely treated with frontline nilotinib or dasatinib, according to a new study by Cortez et al from MD Anderson Cancer Center, USA.

?The 69% of those with normal organ function who achieved molecular response of 4.5 log reduction of bcr-c.abl messenger RNA (an MR4.5 response) is almost identical to the 64% MR4.5 response seen in patients with liver dysfunction (P = .617) and 60% of those renal dysfunction (P = .565).? These results were published in the March issue of Clinical Lymphoma, Myeloma, & Leukemia.

CML is the commonest blood cancer in India. It is regularly treated at Asian Cancer Institute ?- including with both these drugs (nilotinib and dasatinib). We also assist in procuring these medicines from the manufacturer to reduce cost.

Asian Cancer Institute